Summit Therapeutics launches Phase III HARMONi-10, comparing ivonescimab with durvalumab as consolidation therapy in unresectable Stage III NSCLC.
Written By: Kalyani Boharapi, M.Pharm (RA)
Reviewed By: Pharmacally Editorial Team
Summit Therapeutics announced on November 18, 2026, the initiation of HARMONi-10 (Protocol SMT112-3010), a global Phase III trial evaluating its investigational PD-1 × VEGF bispecific antibody, ivonescimab, against durvalumab in patients with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC).
The study will enrol patients whose disease has not progressed following definitive, platinum-based concurrent chemoradiation therapy. Both treatments will be evaluated as consolidation therapy, administered after initial curative-intent treatment to maintain disease control and delay cancer recurrence or progression.
HARMONi-10 is a multi-regional, open-label, potentially registration-enabling study. Its European Clinical Trials Information System (CTIS) registration (2026-526300-67-00) lists 830 planned participants across eight countries and 64 clinical trial sites. Global site activations are expected to begin in the fourth quarter of 2026.
The primary endpoint is progression-free survival (PFS), assessed by an independent radiographic review committee (IRRC) using RECIST version 1.1. Secondary endpoints include overall survival (OS), overall response rate (ORR), time to distant metastasis or death, safety, pharmacokinetics, immunogenicity and patient-reported quality-of-life outcomes.
Ivonescimab Expands into Locally Advanced NSCLC
HARMONi-10 represents Summit’s sixth sponsored Phase III study of ivonescimab and its fourth in NSCLC, following HARMONi, HARMONi-3 and HARMONi-7. It extends the programme into locally advanced disease, where up to 12 months of durvalumab consolidation following concurrent chemoradiation, established by the PACIFIC trial, is the standard of care.
Ivonescimab combines PD-1 checkpoint inhibition with VEGF-mediated anti-angiogenic activity in a single tetravalent molecule. Its cooperative binding to both targets is designed to enhance avidity and retention within the tumour microenvironment. HARMONi-10 will test whether this dual-targeting approach translates into improved clinical outcomes compared with established PD-L1 inhibition.
Broader Clinical Programme Context
Summit’s ivonescimab programme spans NSCLC, colorectal cancer and urothelial carcinoma, alongside collaborative development across multiple tumour types. The company reported five positive Phase III readouts before the HARMONi-10 announcement, including four in NSCLC and one in biliary tract cancer (HARMONi-GI1).
Notably, HARMONi-GI1, conducted by Akeso in China, demonstrated statistically significant OS improvement with ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy in first-line advanced biliary tract cancer. These findings provide a clinical precedent for comparison against a durvalumab-containing regimen but cannot establish efficacy in Stage III NSCLC consolidation therapy.
Regulatory Status and FDA Complete Response Letter
Originally developed by Akeso Inc., ivonescimab received its first marketing authorisation in China in May 2024. It remains investigational in Summit’s licensed territories, including the United States and Europe, where it is designated SMT112; it is known as AK112 elsewhere.
On November 15, 2026, the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Summit’s Biologics License Application (BLA), based on HARMONi. The trial evaluated ivonescimab plus platinum-based chemotherapy in locally advanced or metastatic non-squamous NSCLC with EGFR mutations following prior third-generation EGFR tyrosine kinase inhibitor treatment.
The FDA concluded that the statistically significant but modest median PFS improvement did not establish a favourable benefit-risk profile without a statistically significant OS benefit. It also identified additional serious immune-related and VEGF-inhibition toxicities.
The agency questioned the applicability of the findings to US patients because 60% of the study population was enrolled in China, accounting for 93% of PFS events. Chinese enrolment occurred between January and November 2022, while North American and European enrolment began in May 2023. The FDA also considered post-hoc survival analyses exploratory because of different regional data-cutoff dates and earlier termination of follow-up in China. It recommended a new adequate, well-controlled multi-regional trial demonstrating a statistically significant and clinically meaningful benefit sufficient to outweigh the observed toxicity profile.
Strategic Implications for HARMONi-10
The CRL concerns a different indication and treatment regimen and does not constitute a regulatory assessment of HARMONi-10. Nevertheless, it highlights the importance of balanced multi-regional enrolment, consistent follow-up and robust survival evidence.
HARMONi-10 expands ivonescimab’s investigation into curative-intent Stage III NSCLC. Its head-to-head comparison with durvalumab will determine whether dual PD-1 and VEGF inhibition can deliver a clinically meaningful alternative to established consolidation therapy, with efficacy, OS and safety outcomes central to its potential clinical and regulatory relevance.
Reference
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer, Summit Therapeutics, 18 November 2026
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.
